Gold Lyssa T, Masson Glenn R
Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee, Scotland, U.K.
Biochem Soc Trans. 2022 Apr 29;50(2):737-745. doi: 10.1042/BST20211252.
GCN2 (general control nonderepessible 2) is an eIF2α kinase responsible for entirely rewiring the metabolism of cells when they are put under amino acid starvation stress. Recently, there has been renewed interest in GCN2 as a potential oncotarget, with several studies reporting the development of small molecule inhibitors. The foundation of this work is built upon biochemical and cellular data which suggest GCN2 may be aberrantly overexpressed and is responsible for keeping cells on 'life-support' while tumours undergo significant nutritional stress during tumorigenesis, allowing cancer stem cells to develop chemotherapeutic resistance. However, most studies which have investigated the role of GCN2 in cancer have been conducted in various cancer model systems, often under a specific set of stresses, mutational backgrounds and drug cocktails. This review aims to comprehensively summarise the biochemical, molecular and cellular literature associated with GCN2 and its role in various cancers and determine whether a consensus can be developed to discern under which circumstances we may wish to target GCN2.
GCN2(一般控制非抑制性2)是一种真核起始因子2α激酶,当细胞处于氨基酸饥饿应激状态时,它负责全面重塑细胞的代谢。最近,人们对GCN2作为一种潜在的肿瘤靶点重新产生了兴趣,有几项研究报道了小分子抑制剂的研发。这项工作的基础建立在生化和细胞数据之上,这些数据表明GCN2可能异常过度表达,并且在肿瘤发生过程中肿瘤经历显著的营养应激时,负责维持细胞的“生命支持”,从而使癌症干细胞产生化疗耐药性。然而,大多数研究GCN2在癌症中作用的实验是在各种癌症模型系统中进行的,通常处于特定的应激、突变背景和药物组合条件下。本综述旨在全面总结与GCN2相关的生化、分子和细胞文献及其在各种癌症中的作用,并确定是否能够达成共识,以辨别在哪些情况下我们可能希望靶向GCN2。